Clinical Trials · NCT06297616
A Study of LY3841136 in Japanese Participants With Obesity or Overweight
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 128
- Start date
- Apr 2024
- Locations
- 3 sites, Japan
- Primary endpoint
- Part A: Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration at Week 22